Ceftaroline in the treatment of Staphylococcus aureus resistant methicilin infection in clinical practice
2019
Abstract
Staphylococcus aureus including methicilin resistant strains (methicillin-resistant Staphylococcus aureus, MRSA) is one of the most frequent causative agent of bacterial infection, generally. Treatment of MRSA infections is limited by the availability of effective drugs.
Ceftaroline, fifth generation of cephalosporin, is one of them. Approved indications are community acquired pneumonia and complicated skin and soft tissue infections.
Observational studies proved clinical efficacy and safety of ceftaroline for treatment of bloodstream infections.